Nov 2-6, 2020, Festival of Biologics, Basel, Switzerland
Nov 9-13, 2020, PEGS Europe, Lisbon, Portugal
Nov 9-14, 2020, SITC
Healthcare Direkt - Interview with Martin Welschof, CEO, October 28, 2020 > Interview
Di – License agreement BI-1206 for China, October 27, 2020 > Link
Di tv - Interview with Martin Welschof, CEO, October 27, 2020 > Interview
Pareto-TV - Interview with Martin Welschof, CEO, October 27, 2020 > Interview
Interview with Dharminder Chahal, Board member of BioInvent, September 23, 2020 > Interview
Key Opinion Leader call – July 21, 2020 > Replay
BioInvent develops antibodies for the treatment of cancer
BioInvent is generating value for shareholders by employing its antibody and cancer biology expertise to identify antibodies with novel mechanisms-of-action and novel oncology targets. The Company employs this approach to generate therapeutic immuno-modulating antibodies that can be developed for a broad range of cancer indications. The Company plans to bring these antibodies to the clinic through its own resources and together with partners.
Immuno-oncology - a revolution in cancer treatment
The body’s immune defense is one of the most effective weapons to fight cancer. Development of new immuno-oncology drugs directing the immune defense against the tumour is expected to revolutionize the treatment.
Two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively.
A collaboration with Pfizer Inc. for the development and commercialization of new antibody therapies directed towards tumor associated myeloid cells.
BI-1808 and BI-1910
BioInvent has identified TNFR2, a member of the so called TNFR superfamily as a target within the Treg program.
BioInvent and Transgene collaborate to co-develop oncolytic virus candidates encoding a validated anti-CTLA-4 antibody sequence.
Our tools for successful drug development
In an automated process, we select new drug candidates from our own antibody library – one of the largest in the world.
Our unique and patented development tool has the advantage of simultaneously identifying disease-associated targets and antibodies that bind to them.